Heterologous chimpanzee adenovirus vector immunizations for SARS-CoV-2 spike and nucleocapsid protect hamsters against COVID-19-Reference-Cited by-同舟云学术

Heterologous chimpanzee adenovirus vector immunizations for SARS-CoV-2 spike and nucleocapsid protect hamsters against COVID-19

Published:2023-05 Issue:4 Volume:25 Page:105082
ISSN:1286-4579
Container-title:Microbes and Infection
language:en
Short-container-title:Microbes and Infection

Author:

Hasanpourghadi Mohadeseh,Novikov Mikhail,Ambrose Robert,Chekaoui Arezki,Newman Dakota^ORCID,Ding Jianyi,Giles-Davis Wynetta,Xiang Zhiquan,Zhou Xiang Yang,Liu Qin^ORCID,Swagata Kar,Ertl Hildegund CJ.^ORCID

Funder

G Harold and Leila Y Mathers Foundation

Janssen Scientific Affairs LLC

Commonwealth of Pennsylvania Department of Labor and Industry

Publisher

Elsevier BV

Subject

Infectious Diseases,Immunology,Microbiology

Reference44 articles.

1. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2;Liu;Nature,2022

2. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine;Baden;N Engl J Med,2021

3. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine;Polack;N Engl J Med,2020

4. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19;Sadoff;N Engl J Med,2021

5. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial;Emary;Lancet,2021

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revolutionizing Veterinary Health with Viral Vector-Based Vaccines;Indian Journal of Microbiology;2024-06-21

2. Preclinical Immunogenicity and Efficacy Studies for Therapeutic Vaccines for Human Papillomavirus-Type-16-Associated Cancer;Vaccines;2024-06-04

3. Immunogenicity and safety of a live-attenuated SARS-CoV-2 vaccine candidate based on multiple attenuation mechanisms;2024-04-26

4. Immunogenicity and safety of a live-attenuated SARS-CoV-2 vaccine candidate based on multiple attenuation mechanisms;2024-04-26

5. Immunogenicity and safety of a live-attenuated SARS-CoV-2 vaccine candidate based on multiple attenuation mechanisms;2024-03-04